Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
CALGARY, Alberta, Oct. 02, 2017 -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that its Annual Meeting of Shareholders (the “Meeting”) is to be held Tuesday, December 12, 2017 at Mount Royal University, Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 2:45 pm (MT).
A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and filed on SEDAR at www.sedar.com in early November, 2017.
Following the formal business of the Meeting, Mr. Donald J. McCaffrey, President and Chief Executive Officer, will deliver a corporate update presentation. The presentation will be available via live webcast.
| Webcast Details: | |
| Date: | Tuesday, December 12, 2017 |
| Time: | Approximately 3:00 pm (MT) – following the formal business of the Meeting |
| Webcast Link: | Click hear to launch the webcast viewer |
The presentation will be available on the Company’s website immediately prior to the start of the event. Click on this LINK to go directly to the appropriate page on the Company’s website.
An archived replay of the webcast will also be available on the Company website by clicking on this LINK.
About Zenith
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact:
Clayton Paradis
Zenith Capital Corp.
Phone: 587-390-7865
Email: [email protected]
